Navigation Links
Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
Date:1/12/2009

RIDGEFIELD, Conn., Jan. 12 /PRNewswire/ -- Boehringer Ingelheim today announced the appointment of Albert Ros as executive vice president of Sales and Marketing for the company's Prescription Medicines Business. In his new role, Ros will lead the U.S. sales and marketing strategy of Boehringer Ingelheim's core brands.

"We are pleased to have Albert in such an important leadership role," said J. Martin Carroll, President and Chief Executive Officer, Boehringer Ingelheim Corporation. "Albert is a valuable member of the Boehringer Ingelheim team and he possesses an impressive range of global sales and marketing experience."

Ros has been with Boehringer Ingelheim for 14 years and previously served as Head of Boehringer Ingelheim's Corporate Division for Marketing of Prescription Medicines. In this position, which he held since 2005, Ros led the development of four global products including Spiriva(R), Flomax(R), Mirapex(R) and Micardis(R). Previously, Ros served as the country manager for Boehringer Ingelheim Brazil and the business unit head of Boehringer Ingelheim Spain.

Ros earned a pharmacy degree from the University of Barcelona, a master's degree in business administration from ESADE Business School in Barcelona, and a post graduate degree in general management from IESE Business School in Barcelona. Ros and his wife and three sons will relocate to Ridgefield, Connecticut in early 2009.

About Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Novo Nordisk Appoints New Leader of North American Business
3. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
4. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
5. Resonant Medical Appoints New Vice President of Global Sales
6. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
7. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
8. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
9. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
10. Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA
11. Adlyfe Appoints Roxanne Duan as Vice President of Research

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)....,Nov.24/PRNewswire/--Nextmonth,UnitedHealthcarewi...ingHispanic-AmericanseniorsunderstandthebasicsofMe...akeafreeZumba®Goldclass,aLatin-infusedfitness...,rumba,andtango. ,, UnitedHealthcarewillofferth...ndengagedwhenlearningabouttheirhealthcareoptions. ...
(Date:11/24/2009)...RNewswire/--TheUnionLaborLifeInsuranceCompany("Uni...(®),()thenation,slargestvisionbenefitsandserv...tstounions,uniontrustfunds,unionemployersandtheirm...ngservicesincludingcomprehensiveeyeexams,broadsele...tantqualityeyecareis,"statedBruceSmith,NationalSal...
(Date:11/24/2009)...ay help ward off peripheral artery disease, resea...ay News) -- Among people aged 75 and older, the he...rt attacks, stroke or death, a new study finds. ,...remedy might help prevent the leg-circulation prob..., Ginkgo contains nutrients called flavonoids, w...
(Date:11/24/2009)...n,t differ greatly between high- and low-volume ce...(HealthDay News) -- Do hospitals that conduct the ...sults for patients? Maybe not. , Prior research...it comes to artery-opening procedures, but a new s... high-volume hospitals performing more or less equ...
(Date:11/24/2009)...nd, Calif. A study conducted by Children,s Hospit... a new class of therapeutic agents found naturally...cancer, the third most deadly form of cancer. Sphi...in soy that research shows may be the key to fight..., MD, PhD, senior scientist and director of the Ca...
Breaking Medicine News(10 mins):Health News:UnitedHealthcare To Offer Seniors Hispanic-Centered Medicare Education Seminars Combined With a Latin-Themed Fitness Program 2Health News:Union Labor Life & VSP Vision Care Align to Offer Vision Insurance Products 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 3Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3Health News:Children's Hospital Oakland scientists discover soy component may be key to fighting colon cancer 2
...n beings only as recently as between 13,000 and 17...arlier theories contend that the bond // lasted si...Darcy Morey, and takes canine burials into conside...ot become common between 15,000 and 14,000 years a...
...tter than cure” is the mantra for a new study that...heart. // Strategies to manage stress in Ame...According to research 20 percent of Americans are ...duce stress in the short term, they are precursors...
...ve launched the SV40 Cancer Foundation in memory o... an SV40 positive brain tumor. // The main aim of ...independent research and to facilitate clinical im...ates both the Inactivated Polio Vaccine (IPV) of D...
... Whitaker, parents of Charlie Whitaker, afflicted ...n Anemia appeal to the Human Fertilization and Emb...igner baby’ concept to save their sick child. Diam...g with a perfect tissue match is the only viable t...
...rvice NHS 24 has said that there has been a comple...ated in the working of the system. // This was don... timely help from the NHS 24 service. The deat...d called the help line but due to the delays in of...
...rch 2006(forthcoming) issue of the Journal of Cons...ts of people revealed that eating habits are made ...Khare (University of Houston) and J. Jeffrey Inman...ine habit." The main point with carryover habi...
Other Medicine News:Health News:Designer Babies- To Create Or Not To Create! 2Health News:Designer Babies- To Create Or Not To Create! 3Health News:NHS 24: A complete makeover 2
(Date:11/24/2009)..., XI,AN,China,Nov.24/PRNewswire-Asia/--HuifengBi...HFGB),aleadingdeveloperandproducer,ofplantextracts...l,nutraceuticalandfoodproductioninXi,an,China,tod...da26%increaseinrevenues. , Revenuesforthequar...31,147,or26%,from$3,534,623forthesamequarterin2008...
(Date:11/24/2009)..., NORTHHOLLYWOOD,Calif.,Nov.24/PRNewswire-FirstC...,aleadingnationalhospitalistphysiciangrouppractice...anIPChospitalist,wasnamedby ACPHospitalist asoneof...edintheNovember2009issueofthemagazine. ,, Dr.Va...andcurrentlyservesasdirectorofhospitalmedicineatSt...
(Date:11/24/2009)..., WARSAW,Ind.,Nov.24/PRNewswire-FirstCall/--Zimm...twillbeparticipatinginthe21stAnnualPiperJaffrayHea...9,at8:00a.m.EasternTime. ,, Alivewebcastofthepr...swebsiteat http://investor.zimmer.com .Thewebcastw..., AbouttheCompany ,, Foundedin1927andheadquar...
Breaking Medicine Technology:Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 2BioWa and NKTT Announce Licensing of BioWas POTELLIGENT 28R 29 Technology For Use in Antibody Research and Development 14560 1BioWa and NKTT Announce Licensing of BioWas POTELLIGENT 28R 29 Technology For Use in Antibody Research and Development 14560 2BioWa and NKTT Announce Licensing of BioWas POTELLIGENT 28R 29 Technology For Use in Antibody Research and Development 14560 3Gamida Cell and Cellerix Partner on Feasibility Study 14558 1Gamida Cell and Cellerix Partner on Feasibility Study 14558 2Gamida Cell and Cellerix Partner on Feasibility Study 14558 3Delcath Systems Inc Completes Phase III Study Enrollment 5635 1Delcath Systems Inc Completes Phase III Study Enrollment 5635 2Delcath Systems Inc Completes Phase III Study Enrollment 5635 3
...v. 20 Clinical data from a prospective,registry p...ium shows DVT,treatment with the Trellis(R) Periph...Santa Clara, CA) successfully breaks up the blood ... This technique, called isolated pharmacomechanica...nd safely than current catheter-directed thromboly...
...ay, November 20 The Scandinavian-based drug,devel...ts of studies on its,lead antimicrobial candidate ...studies showed that the novel lytic peptidomimetic...antly better towards killing Staphylococcus,aureus...ndard drugs. In,addition to this it has proven eff...
Other Medicine Technology:Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2
...e new Finnpipette Focus from Thermo Labsystems was...uncompromising performance. Advanced features suc...me adjustment on microvolumes help to define this ...w interchangeable handle plate offers a custom fit...
...e Eppendorf Reference Series 2000 Pipette is a syn...mpact and robust design, and superior operating co...to operate the measuring stroke and blow-out as we... "pipette/tip" system ensures utmost accuracy and ...
...e Integrity family of pacemakers features several ...n today's worldwide pacing market. Offering an unp...agnostic information, the system builds on the pop... ,It incorporates the exclusive ventricular Auto...
...e Identity pacemaker family, which includes the wo...inicians with the most advanced pacemaker technolo...ession algorithm, the first and only U.S. commerci...l fibrillation (AF). The AF Suppression algorithm ...
Medicine Products: